Mr. Kan Chen is a Principal of Qiming Venture Partners, focusing on healthcare investment.
Before joining Qiming Venture Partners, Kan was a senior scientist at Johnson&Johnson discovering innovative cancer medicine. Prior to that, Kan was a group leader at Jiangsu Hengrui Medicine, developing new cancer immunotherapies.
Kan earned his PhD degree in Cell Biology from Case Western Reserve University in the U.S. and finished his postdoctoral training in Immunology at Harvard Medical School. He got his bachelor’s degree in biological sciences from Fudan University.